Clinical Trials in Adelaide, South Australia
7 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled35 locationsNCT07085767
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled21 locationsNCT07100106
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled10 locationsNCT07222267
Recruiting
Phase 1
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Advance Solid Tumors
Kivu Bioscience Inc.76 enrolled4 locationsNCT07229313
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+1 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm FemaleRadiotherapyCosmetic Outcome
Ontario Clinical Oncology Group (OCOG)910 enrolled27 locationsNCT05417516
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeiGene300 enrolled63 locationsNCT06120283
Recruiting
Phase 1
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics60 enrolled5 locationsNCT07334119
Recruiting
Early Phase 1
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
PDL1 Gene Mutation
Radiopharm Theranostics, Ltd30 enrolled5 locationsNCT06305962
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled14 locationsNCT07173751
Recruiting
Not Applicable
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Breast CancerBreast Cancer Female
Breast Cancer Trials, Australia and New Zealand1,400 enrolled9 locationsNCT06445738
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled153 locationsNCT07062965
Recruiting
Phase 1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
BioNTech SE280 enrolled45 locationsNCT05142189
Recruiting
Phase 1
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Metastatic Breast CancerAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)+3 more
Olema Pharmaceuticals, Inc.180 enrolled8 locationsNCT06784193
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company540 enrolled49 locationsNCT04956640
Recruiting
Phase 1
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorMetastatic Ovarian Cancer+3 more
EtiraRx Australia Pty Ltd15 enrolled4 locationsNCT06533332
Recruiting
Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled41 locationsNCT04606446